These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6812245)

  • 1. Plasma derivatives and viral hepatitis.
    Gerety RJ; Aronson DL
    Transfusion; 1982; 22(5):347-51. PubMed ID: 6812245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of hepatitis B surface antigen in commercially prepared plasma products.
    Hoofnagle JH; Gerety RJ; Thiel J; Barker LF
    J Lab Clin Med; 1976 Jul; 88(1):102-13. PubMed ID: 932529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Post-transfusion hepatitis and its sequelae in the treatment of hemophilia].
    Schimpf K
    Behring Inst Mitt; 1983 Aug; (73):111-7. PubMed ID: 6433878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis transmission by blood products.
    Yap PL
    J Hosp Infect; 1988 Feb; 11 Suppl A():166-74. PubMed ID: 2896702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infection with hepatitis G virus among recipients of plasma products.
    Jarvis LM; Davidson F; Hanley JP; Yap PL; Ludlam CA; Simmonds P
    Lancet; 1996 Nov; 348(9038):1352-5. PubMed ID: 8918279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in risk of hepatitis transmission by heat-treatment of a human Factor VIII concentrate.
    Hollinger FB; Dolana G; Thomas W; Gyorkey F
    J Infect Dis; 1984 Aug; 150(2):250-62. PubMed ID: 6432922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.
    Lancet; 1988 Oct; 2(8615):814-6. PubMed ID: 2902265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of post-transfusion infection with the hepatitis delta virus. A multicenter study.
    Rosina F; Saracco G; Rizzetto M
    N Engl J Med; 1985 Jun; 312(23):1488-91. PubMed ID: 3990749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-transfusion hepatitis and its association with pooled clotting factors.
    Sugg U; Frösner GG; Lissner R; Stunkat R; Schneider W
    Eur J Clin Microbiol; 1983 Apr; 2(2):135-40. PubMed ID: 6407830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic liver dysfunction in multitransfused hemophiliacs.
    Hasiba UW; Spero JA; Lewis JH
    Transfusion; 1977; 17(5):490-4. PubMed ID: 910267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Freedom from transmission of hepatitis-B of gamma-globulin and heat-inactivated plasma protein fraction prepared from contaminated human plasma by fractionation with solid-phase polyelectrolytes.
    Harris RB; Johnson AJ; Semar M; Delente J; Fields JE
    Vox Sang; 1979; 36(3):129-36. PubMed ID: 88811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-A/non-B hepatitis in experimentally infected chimpanzees: cross-challenge and electron microscopic studies.
    Bradley DW; Maynard JE; Cook EH; Ebert JW; Gravelle CR; Tsiquaye KN; Kessler H; Zuckerman AJ; Miller MF; Ling C; Overby LR
    J Med Virol; 1980; 6(3):185-201. PubMed ID: 6785393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Cohn-fractionated Rh immune globulin transmit viral hepatitis?
    Iwarson S; Steen Y; Rybo G; Hermodsson S; Antonsson I; Vietorisz A
    Transfusion; 1985; 25(1):15-7. PubMed ID: 2982222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma concentrates of factor VIII. Where are we?].
    Vicente V
    Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
    [No Abstract]   [Full Text] [Related]  

  • 15. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin.
    Kernoff PB; Lee CA; Karayiannis P; Thomas HC
    Br J Haematol; 1985 Jul; 60(3):469-79. PubMed ID: 3925981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occult hepatitis B infection and transfusion-transmission risk.
    Candotti D; Boizeau L; Laperche S
    Transfus Clin Biol; 2017 Sep; 24(3):189-195. PubMed ID: 28673499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
    Edwards CA; Piet MP; Chin S; Horowitz B
    Vox Sang; 1987; 52(1-2):53-9. PubMed ID: 3111089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.
    Pierce GF; Lusher JM; Brownstein AP; Goldsmith JC; Kessler CM
    JAMA; 1989 Jun; 261(23):3434-8. PubMed ID: 2498537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin preparation: safe from virus transmission?
    Uemura Y; Yokoyama K; Nishida M; Suyama T
    Vox Sang; 1989; 57(1):1-3. PubMed ID: 2508323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver dysfunction in Pennsylvania's multitransfused hemophiliacs.
    Hasiba U; Eyster ME; Gill FM; Kajani M; Lewis JH; Lusch CJ; Prager D; Rice SA; Shapiro SS
    Dig Dis Sci; 1980 Oct; 25(10):776-82. PubMed ID: 6775916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.